Exploratory Clinical Trials of ACM-1 in the Treatment of Ophthalmological Neovascular Diseases

• Status: Unknown status
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the role of intravitreal injection of anti-vascular endothelial growth factor (VEGF) therapy in prevention and control of ophthalmological neovascular diseases, in order to find a new strategy of treatment for ophthalmological neovascular diseases

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University

Criteria

Inclusion Criteria:

1. age range from 18 to 75 years old

2. without light perception (NLP)

3. A large number of iris or retinal neovascularizations, neovascular glaucoma who needs cyclophotocoagulation or enucleation of eyeball

4. The best corrected visual acuity of the contralateral eye is better than 0.05

5. Follow-up for more than six months

6. Volunteer for this project and sign the informed consent

Exclusion Criteria:

1. The best corrected visual acuity of the contralateral eye is lower than 0.05

2. Severe systemic disease or other surgical contraindication

3. history of antiangiogenic therapy within one month

4. Ocular neovascularization was caused by other reasons,such as endophthalmitis

5. history of joining in drug clinical trial within one month(except for vitamins and minerals)

6. pre-menopausal women who do not use birth control

7. people are currently being treated for systemic infections

8. Allergic to fluorescein

9. hypertension(SBP is higher than 140mmHg)

10. hepatic renal dysfunction

11. History of drug abuse or alcoholism

12. other situation which will impede the clinical trial, as such depressive disorder

13. the compliance is too poor to finish the clinical trial